Browse PIK3R5

Summary
SymbolPIK3R5
Namephosphoinositide-3-kinase, regulatory subunit 5
Aliases P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Cell membrane Peripheral membrane protein Note=Predominantly localized in the nucleus in absence of PIK3CG/p120. Colocalizes with PIK3CG/p120 in the cytoplasm. Translocated to the plasma membrane in a beta-gamma G protein-dependent manner.
Domain PF10486 Phosphoinositide 3-kinase gamma adapter protein p101 subunit
Function

Regulatory subunit of the PI3K gamma complex. Required for recruitment of the catalytic subunit to the plasma membrane via interaction with beta-gamma G protein dimers. Required for G protein-mediated activation of PIK3CG (By similarity).

> Gene Ontology
 
Biological Process GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006661 phosphatidylinositol biosynthetic process
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008654 phospholipid biosynthetic process
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0019216 regulation of lipid metabolic process
GO:0030168 platelet activation
GO:0030258 lipid modification
GO:0033674 positive regulation of kinase activity
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043491 protein kinase B signaling
GO:0043550 regulation of lipid kinase activity
GO:0043551 regulation of phosphatidylinositol 3-kinase activity
GO:0045017 glycerolipid biosynthetic process
GO:0045860 positive regulation of protein kinase activity
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:1903725 regulation of phospholipid metabolic process
Molecular Function GO:0019207 kinase regulator activity
GO:0031683 G-protein beta/gamma-subunit complex binding
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0035014 phosphatidylinositol 3-kinase regulator activity
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0046935 1-phosphatidylinositol-3-kinase regulator activity
GO:0052813 phosphatidylinositol bisphosphate kinase activity
Cellular Component GO:0005942 phosphatidylinositol 3-kinase complex
GO:0005944 phosphatidylinositol 3-kinase complex, class IB
GO:0019898 extrinsic component of membrane
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0097651 phosphatidylinositol 3-kinase complex, class I
> KEGG and Reactome Pathway
 
KEGG hsa04022 cGMP-PKG signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04611 Platelet activation
hsa04725 Cholinergic synapse
hsa04921 Oxytocin signaling pathway
Reactome R-HSA-392451: G beta
R-HSA-397795: G-protein beta
R-HSA-388396: GPCR downstream signaling
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-109582: Hemostasis
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1483255: PI Metabolism
R-HSA-1483257: Phospholipid metabolism
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-1660499: Synthesis of PIPs at the plasma membrane
Summary
SymbolPIK3R5
Namephosphoinositide-3-kinase, regulatory subunit 5
Aliases P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PIK3R5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PIK3R5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21665146Breast NeoplasmInhibit immunityOnce activated, p110γ promotes inside-out activation of a single integrin, α4β1, causing myeloid cell invasion into tumors. Pharmacological or genetic blockade of p110γ suppressed inflammation, growth, and metastasis of implanted and spontaneous tumors, revealing an important therapeutic target in oncology.
Summary
SymbolPIK3R5
Namephosphoinositide-3-kinase, regulatory subunit 5
Aliases P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PIK3R5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPIK3R5
Namephosphoinositide-3-kinase, regulatory subunit 5
Aliases P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PIK3R5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2970.327
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3640.663
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2510.715
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0350.944
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4090.811
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6050.802
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0840.857
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3890.743
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2880.831
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4720.141
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9760.191
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0680.709
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PIK3R5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277306.8-6.80.32
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 1113015.4-15.40.482
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512016.7-16.71
Summary
SymbolPIK3R5
Namephosphoinositide-3-kinase, regulatory subunit 5
Aliases P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PIK3R5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPIK3R5
Namephosphoinositide-3-kinase, regulatory subunit 5
Aliases P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PIK3R5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PIK3R5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPIK3R5
Namephosphoinositide-3-kinase, regulatory subunit 5
Aliases P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PIK3R5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPIK3R5
Namephosphoinositide-3-kinase, regulatory subunit 5
Aliases P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PIK3R5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPIK3R5
Namephosphoinositide-3-kinase, regulatory subunit 5
Aliases P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PIK3R5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPIK3R5
Namephosphoinositide-3-kinase, regulatory subunit 5
Aliases P101-PI3K; p101; F730038I15Rik; FOAP-2; PI3-kinase p101 subunit; phosphatidylinositol 4,5-bisphosphate 3-kin ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PIK3R5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.